Skip to main content

Advertisement

SpringerLink
Log in

Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis

  • Original Article
  • Published:
The Pharmacogenomics Journal Submit manuscript

Abstract

Oncologists have pointed out an urgent need for biomarkers that can be useful for clinical application to predict the susceptibility of patients to preoperative therapy. This review collects, evaluates and combines data on the influence of reported somatic and germline genetic variations on histological tumor regression in neoadjuvant settings of rectal and esophageal cancers. Five hundred and twenty-seven articles were identified, 204 retrieved and 61 studies included. Among 24 and 14 genetic markers reported for rectal and esophageal cancers, respectively, significant associations in meta-analyses were demonstrated for the following markers. In rectal cancer, major response was more frequent in carriers of the TYMS genotype 2 R/2 R-2 R/3 R (rs34743033), MTHFR genotype 677C/C (rs1801133), wild-type TP53 and KRAS genes. In esophageal cancer, successful therapy appeared to correlate with wild-type TP53. These results may be useful for future research directions to translate reported data into practical clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Glimelius B . Radiotherapy in rectal cancer. Br Med Bull 2002; 64: 141–157.

    CAS  PubMed  Google Scholar 

  2. Mansour JC, Schwarz RE . Pathologic response to preoperative therapy: does it mean what we think it means? Ann Surg Oncol 2009; 16: 1465–1479.

    PubMed  Google Scholar 

  3. Bai X, Li S, Yu B, Su H, Jin W, Chen G et al. Sphincter-preserving surgery after preoperative radiochemotherapy for T3 low rectal cancers. Oncol Lett 2012; 3: 1336–1340.

    PubMed  PubMed Central  Google Scholar 

  4. McLeod HL . Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013; 339: 1563–1566.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Hertz DL, McLeod HL . Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013; 58: 346–352.

    CAS  PubMed  Google Scholar 

  6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.

    CAS  PubMed  Google Scholar 

  7. Walker AS, Zwintscher NP, Johnson EK, Maykel JA, Stojadinovic A, Nissan A et al. Future directions for monitoring treatment response in colorectal cancer. J Cancer 2014; 5: 44–57.

    PubMed  PubMed Central  Google Scholar 

  8. Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 2009; 13: 1411–1421.

    PubMed  Google Scholar 

  9. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 2010; 17: 1159–1167.

    PubMed  Google Scholar 

  10. Thies S, Langer R . Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol 2013; 3: 262.

    PubMed  PubMed Central  Google Scholar 

  11. Yu B, Zheng Y, Alexander D, Morrison AC, Coresh J, Boerwinkle E . Genetic determinants influencing human serum metabolome among African Americans. PLoS Genet 2014; 10: e1004212.

    PubMed  PubMed Central  Google Scholar 

  12. Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 2012; 7: e45388.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Clancy C, Burke JP, Coffey JC . KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol 2013; 22: 105–111.

    PubMed  Google Scholar 

  14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.

    Article  CAS  PubMed  Google Scholar 

  15. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686.

    CAS  PubMed  Google Scholar 

  16. Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19–23.

    CAS  PubMed  Google Scholar 

  17. Schwarzer G. Meta: meta-analysis with R. R package version 4.0-3. 2015. http://CRAN.R-project.org/package=meta.

  18. Core Team. R . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2014. http://www.R-project.org/.

    Google Scholar 

  19. Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ioannidis JP, Trikalinos TA . The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007; 176: 1091–1096.

    PubMed  PubMed Central  Google Scholar 

  21. Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys 2011; 81: 1319–1327.

    PubMed  Google Scholar 

  22. Uemura N, Kondo T . Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol 2014; 5: 322–334.

    PubMed  PubMed Central  Google Scholar 

  23. Falchook AD, Tepper JE . Rectal cancer genomics. Semin Colon Rectal Surg 2014; 25: 13–18.

    Google Scholar 

  24. Findlay JM, Middleton MR, Tomlinson I . A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol 2014; 26: 624–644.

    PubMed  PubMed Central  Google Scholar 

  25. Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J Cancer Res Clin Oncol 2010; 136: 1681–1689.

    PubMed  Google Scholar 

  26. Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 2011; 29: 875–883.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Ghosh S, Hossain MZ, Borges M, Goggins MG, Ingersoll RG, Eshleman JR et al. Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies. PLoS One 2012; 7: e34426.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK . Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics 2012; 22: 290–304.

    CAS  PubMed  Google Scholar 

  29. Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A et al. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 2011; 105: 1654–1662.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI . Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134–144.

    CAS  PubMed  Google Scholar 

  31. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G, Iacopetta B . The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003; 9: 5860–5865.

    CAS  PubMed  Google Scholar 

  32. Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 2011; 11: 214–226.

    CAS  PubMed  Google Scholar 

  33. Sohn KJ, Jang H, Campan M, Weisenberger DJ, Dickhout J, Wang YC et al. The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int J Cancer 2009; 124: 1999–2005.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. De Mattia E, Toffoli G . C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333–1351.

    CAS  PubMed  Google Scholar 

  35. Li P, Chen Q, Wang YD, Ha MW . Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer. Genet Test Mol Biomarkers 2014; 18: 313–322.

    CAS  PubMed  Google Scholar 

  36. Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2009; 16: 1–12.

    CAS  PubMed  Google Scholar 

  37. Walerych D, Napoli M, Collavin L, Del Sal G . The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33: 2007–2017.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Eguchi K, Yao T, Konomoto T, Hayashi K, Fujishima M, Tsuneyoshi M . Discordance of p53 mutations of synchronous colorectal carcinomas. Mod Pathol 2000; 13: 131–139.

    CAS  PubMed  Google Scholar 

  39. Munro AJ, Lain S, Lane DP . P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434–444.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157–1167.

    CAS  PubMed  Google Scholar 

  41. Krishnan S, Chang GJ . KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy? Ann Surg Oncol 2013; 20: 3359–3362.

    PubMed  Google Scholar 

  42. Wojczynski MK, Tiwari HK . Definition of fhenotype. Rao DC, Gu CC (eds). Genetic Dissection of Complex Traits, 2nd edn. Academic Press Elsevier: San Diego, 2008, pp 75–104.

    Google Scholar 

  43. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688–8696.

    PubMed  Google Scholar 

  44. Yasutomi M, Baba S, Hojo K, Kato Y, Kodaira S, Koyama Y et al Japanese Classification of Colorectal Carcinoma. First English edition. Kanehara and Co., Ltd.: Tokyo, Japan, 1997.

    Google Scholar 

  45. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7–18.

    CAS  PubMed  Google Scholar 

  46. Gavioli M, Bagni A, Piccagli I, Fundaro S, Natalini G . Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Dis Colon Rectum 2000; 43: 1075–1083.

    CAS  PubMed  Google Scholar 

  47. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 2002; 45: 1051–1056.

    CAS  PubMed  Google Scholar 

  48. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521–1530.

    PubMed  Google Scholar 

  49. Baldus SE, Mönig SP, Schröder W, Metzger R, Lang S, Zirbes TK et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 2004; 25: 4780–4788.

    Google Scholar 

  50. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684–692.

    PubMed  PubMed Central  Google Scholar 

  51. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A . American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edn. Springer, Inc.: Chicago, IL, USA, 2010.

    Google Scholar 

  52. Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, Finnegan T et al. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat Oncol 2011; 13: 114.

    Google Scholar 

  53. Dzhugashvili M, Luengo-Gil G, García T, González-Conejero R, Conesa-Zamora P, Escolar PP et al. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2014; 90: 595–602.

    PubMed  Google Scholar 

  54. Villafranca E, Okruzhnov Y, Dominguez MA, García-Foncillas J, Azinovic I, Martínez E et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 1: 1779–1786.

    Google Scholar 

  55. Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A . Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006; 66: 500–504.

    PubMed  Google Scholar 

  56. Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006; 16: 817–824.

    CAS  PubMed  Google Scholar 

  57. Ho-Pun-Cheung A, Assenat E, Thezenas S, Bibeau F, Rouanet P, Azria D et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1094–1101.

    CAS  PubMed  Google Scholar 

  58. Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A . Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 2007; 50: 1363–1369.

    PubMed  Google Scholar 

  59. Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett 2008; 272: 221–225.

    CAS  PubMed  Google Scholar 

  60. Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro-Muñoz C, Lopez R et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 2010; 11: 747–761.

    CAS  PubMed  Google Scholar 

  61. Grimminger PP, Brabender J, Warnecke-Eberz U, Narumiya K, Wandhöfer C, Drebber U et al. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 2010; 164: e61–e66.

    CAS  PubMed  Google Scholar 

  62. Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K et al. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol 2011; 18: 2442–2452.

    PubMed  PubMed Central  Google Scholar 

  63. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 2011; 254: 486–492.

    PubMed  Google Scholar 

  64. Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Thezenas S et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J 2011; 11: 437–443.

    CAS  PubMed  Google Scholar 

  65. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res 2011; 17: 5161–5169.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Hur H, Kang J, Kim NK, Min BS, Lee KY, Shin SJ et al. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2011; 81: 669–676.

    CAS  PubMed  Google Scholar 

  67. Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B et al. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 2012; 82: 138–144.

    CAS  PubMed  Google Scholar 

  68. Arrazubi V, Suárez J, Guerrero D, Gómez M, Viúdez A, Arias F et al. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Colorectal Dis 2013; 15: 428–435.

    CAS  PubMed  Google Scholar 

  69. Kim JC, Ha YJ, Roh SA, Cho DH, Choi EY, Kim TW et al. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 2013; 86: 350–357.

    CAS  PubMed  Google Scholar 

  70. Sebio A, Salazar J, Páez D, Berenguer-Llergo A, Del Río E, Tobeña M et al. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. Pharmacogenomics J 2014; 15: 77–83.

    PubMed  Google Scholar 

  71. Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F . The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 2006; 94: 203–207.

    CAS  PubMed  Google Scholar 

  72. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789–3798.

    CAS  PubMed  Google Scholar 

  73. Alakus H, Warnecke-Eberz U, Bollschweiler E, Mönig SP, Vallböhmer D, Brabender J et al. GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J 2009; 9: 202–207.

    CAS  PubMed  Google Scholar 

  74. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009; 27: 857–871.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, Hsu CH et al. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 2011; 18: 2066–2073.

    PubMed  Google Scholar 

  76. Narumiya K, Metzger R, Bollschweiler E, Alakus H, Brabender J, Drebber U et al. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 2011; 12: 205–214.

    CAS  PubMed  Google Scholar 

  77. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 2688–2698.

    PubMed  Google Scholar 

  78. Chen PC, Chen YC, Lai LC, Tsai MH, Chen SK, Yang PW et al. Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1996–2003.

    CAS  PubMed  Google Scholar 

  79. Metzger R, Warnecke-Eberz U, Alakus H, Kütting F, Brabender J, Vallböhmer D et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16: 26–34.

    PubMed  Google Scholar 

  80. Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M et al. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 2012; 118: 4346–4353.

    CAS  PubMed  Google Scholar 

  81. Yang PW, Hsieh CY, Kuo FT, Huang PM, Hsu HH, Kuo SW et al. The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2013; 20: 562–571.

    PubMed  Google Scholar 

  82. Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R et al. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer 2014; 14: 58.

    PubMed  PubMed Central  Google Scholar 

  83. Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, Kimura A et al. Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. Br J Cancer 1998; 77: 159–166.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003; 46: 192–202.

    PubMed  Google Scholar 

  85. Lopez-Crapez E, Bibeau F, Thezenas S, Ychou M, Simony-Lafontaine J, Thirion A et al. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer 2005; 92: 2114–2121.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009; 13: 469–474.

    Google Scholar 

  87. Zauber NP, Marotta SP, Berman E, Grann A, Rao M, Komati N et al. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys 2009; 13: 472–476.

    Google Scholar 

  88. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 2010; 13: 1019–1024.

    Google Scholar 

  89. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 13: 76–81.

    Google Scholar 

  90. Chen Z, Duldulao MP, Li W, Lee W, Kim J, Garcia-Aguilar J . Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg 2011; 212: e1.

    Google Scholar 

  91. Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1032–1038.

    CAS  PubMed  Google Scholar 

  92. Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels JP et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 2011; 17: 3469–3477.

    CAS  PubMed  Google Scholar 

  93. Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. Int J Radiat Oncol Biol Phys 2011; 81: 677–683.

    CAS  PubMed  Google Scholar 

  94. Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol 2011; 22: 2424–2430.

    CAS  PubMed  Google Scholar 

  95. Sun PL, Li B, Ye QF . Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis 2012; 27: 1325–1332.

    PubMed  Google Scholar 

  96. Velenik V, Ocvirk J, Oblak I, Anderluh F . Cetuximab in preoperative treatment of rectal cancer- term outcome of the XERT trial. Radiol Oncol 2012; 46: 252–257.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Demes M, Scheil-Bertram S, Bartsch H, Fisseler-Eckhoff A . Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. J Gastrointest Oncol 2013; 4: 182–192.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J . Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol 2013; 20: 2166–2171.

    PubMed  PubMed Central  Google Scholar 

  99. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T et al. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys 2013; 87: 992–999.

    CAS  PubMed  Google Scholar 

  100. Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY et al. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Int J Radiat Oncol Biol Phys 2013; 85: 201–207.

    CAS  PubMed  Google Scholar 

  101. Abdul-Jalil KI, Sheehan KM, Toomey S, Schmid J, Prehn J, O'Grady A et al. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. Ann Surg Oncol 2014; 21: 2642–2649.

    PubMed  Google Scholar 

  102. Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY et al. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer 2014; 45: 34–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Sun W, Sun Y, Zhu M, Wang Z, Zhang H, Xin Y et al. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol Rep 2014; 31: 1466–1472.

    CAS  PubMed  Google Scholar 

  104. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A . Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461–6468.

    CAS  PubMed  Google Scholar 

  105. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y et al. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol 2010; 17: 804–811.

    PubMed  Google Scholar 

  106. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622–629.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Fundamental Research Programs of the Russian Academy of Sciences ‘Gene pools and genetic diversity’ (2014).

Author information

Authors and Affiliations

  1. N.I. Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia

    L E Salnikova

  2. Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, The Russian Ministry of Health and Social Development, Moscow, Russia

    L E Salnikova

  3. The Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia

    D S Kolobkov

  4. Institute for Systems Biology Moscow, Moscow, Russia

    D S Kolobkov

Authors
  1. L E Salnikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D S Kolobkov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L E Salnikova.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salnikova, L., Kolobkov, D. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J 16, 249–265 (2016). https://doi.org/10.1038/tpj.2015.46

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2015.46

  • Springer Nature Limited

This article is cited by

Search

Navigation